DTC
VRDN icon

Deep Track Capital’s Viridian Therapeutics VRDN Stock Holding History

Deep Track Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66M Buy
3,592,740
+2,198,796
+158% +$35.4M 0.96% 36
2026
Q1 		$27.3M Sell
1,393,944
-1,130,889
-45% -$33.6M 0.45% 46
2025
Q4 		$78.6M Sell
2,524,833
-2,855,616
-53% -$78.3M 1.4% 19
2025
Q3 		$116M Hold
5,380,449
– – 3.24% 12
2025
Q2 		$75.2M Hold
5,380,449
– – 2.41% 14
2025
Q1 		$72.5M Buy
5,380,449
+857,708
+19% +$14.6M 2.35% 13
2024
Q4 		$86.7M Buy
4,522,741
+771,796
+21% +$16.8M 3.23% 9
2024
Q3 		$85.3M Sell
3,750,945
-172,904
-4% -$2.83M 2.71% 15
2024
Q2 		$51M Buy
3,923,849
+467,796
+14% +$6.48M 1.52% 27
2024
Q1 		$60.5M Sell
3,456,053
-175,675
-5% -$3.41M 1.73% 22
2023
Q4 		$79.1M Buy
3,631,728
+668,461
+23% +$10.6M 2.64% 11
2023
Q3 		$45.5M Buy
2,963,267
+1,683,765
+132% +$32.1M 1.75% 21
2023
Q2 		$30.4M Buy
1,279,502
+49,243
+4% +$1.26M 1.41% 21
2023
Q1 		$31.3M Sell
1,230,259
-540,895
-31% -$17.3M 1.29% 27
2022
Q4 		$51.7M Sell
1,771,154
-199,136
-10% -$4.59M 2.17% 18
2022
Q3 		$40.4M Buy
1,970,290
+800,000
+68% +$14.4M 1.85% 18
2022
Q2 		$13.5M Hold
1,170,290
– – 0.89% 34
2022
Q1 		$21.6M Sell
1,170,290
-166,400
-12% -$3.2M 1.39% 27
2021
Q4 		$26.4M Buy
+1,336,690
New +$24.9M 1.87% 20

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Deep Track Capital's VRDN Position: Q2 2026 in Review

Deep Track Capital increased its Viridian Therapeutics (VRDN) stake by 158% in Q2 2026, buying an estimated $35.4M and bringing the position to 3,592,740 shares worth $66M. The position accounts for 0.96% of the portfolio, ranked #36.

Deep Track Capital first reported a position in VRDN in Q4 2021 and has held it in 19 quarters since. The position peaked at $116M in Q3 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Deep Track Capital held 3,592,740 shares of Viridian Therapeutics worth $66M as of Q2 2026.
  • Deep Track Capital bought 2,198,796 Viridian Therapeutics shares in Q2 2026, an estimated $35.4M.
  • Viridian Therapeutics made up 0.96% of Deep Track Capital's portfolio in Q2 2026, its #36 holding.
  • Deep Track Capital first reported a position in Viridian Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Deep Track Capital's Viridian Therapeutics position peaked at $116M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.